SUPPLEMENTARY APPENDIX 6: Dropped PICO Questions

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis

During the course of the Voting Panel meeting, some PICO questions were dropped due to lack of evidence to make a formal recommendation. The dropped PICO questions are listed below:

1. In children and adolescents with JIA with chronic active uveitis, irrespective of use of topical or systemic therapy, should giving intraocular steroid injections versus not giving intraocular steroid injections be recommended? (PICO 9)

2. In children and adolescents with JIA starting a systemic medication for their arthritis with no history of uveitis, should etanercept versus other TNFi in influencing the incidence of uveitis be recommended? (PICO 14)

3. In children and adolescents with JIA with inactive uveitis, off of topical steroids and needing a change in systemic therapy for active arthritis, should starting etanercept versus another TNFi be recommended? (PICO 16)

4. In children and adolescents with JIA with active CAU regardless of joint disease (assume uveitis guides therapy), should adalimumab versus infliximab as first choice TNFi be recommended? (PICO 17)

5. In children and adolescents with JIA with active CAU regardless of joint activity, should above standard dosing of infliximab (>10 mg/kg/dose every 4 weeks) versus standard JIA dosing be recommended? (PICO 18)

6. In children and adolescents with JIA with active CAU, who have failed TNFi (one or more), should rituximab versus any other medication be recommended? (PICO 25)

7. For children and adolescents with spondyloarthritis starting a TNFi for arthritis, does etanercept versus any other TNFi influence the risk of developing AAU or recurrent AAU? (PICO 30)

8. For children and adolescents with spondyloarthritis starting a TNFi for arthritis, does the choice of TNFi influence the risk of developing AAU or recurrent AAU? (PICO 31)

9. In children and adolescents with spondyloarthritis, are TNFi monoclonal antibodies more effective in decreasing the occurrence or rate of recurrence of episodes of iritis versus etanercept? (PICO 33)